Autoimmune Disease Diagnostics Market

The global autoimmune disease diagnostics market size is estimated to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing awareness about autoimmune diseases, rising activities of research, educational programs, and growing incidences of autoimmune disease.

Get Free Sample Report

Autoimmune disease refers to a type of the body disorder when the own body immune cells attack the other cells and start to destroying them. This occurs due to the malfunctioning of the immune cells to recognize own body cells, organs, tissues, and producing autoantibodies targeting these cells. Autoimmune diseases mostly comprise of the presence of autoantibodies, self-reactive T cells, and inflammation. Based on the report published by the National Institutes of Health (NIH), the autoimmune disorders is one of the deadliest disease and the mortality rate of the disease is high among women. NIH also reported, 23 million Americans were affected by this disease in 2015 and this number was expected to rise in the near future. As per the Arthritis Foundation, nearly 54 million adults reported in the US suffered with arthritis in the year 2017. Additionally, according to the report of the International Diabetes Federation (IDF), around 420 million adults were suffering from diabetes in 2017, and this number was anticipated to surpass 630 million by 2045, worldwide.

Several efforts of various organizations including public and private to create awareness about the disease is a key aspect of the market development. Additionally, various governments are working towards increasing the public awareness among the population so that it encourages the people to undergo early detection and proper treatment of the patient. For example, organizations such as the North American Rheumatoid Arthritis Consortium, Cooperative Study Group for Autoimmune Disease Prevention, and Autoimmunity Centers of Excellence are enthusiastically participating in spreading awareness among the patients as well as healthcare professionals regarding appropriate diagnosis and treatment. The clinicians are also developing new laboratories with advanced technologies to obtain precise and fast results. The automated laboratories are increasing in trend as there are over 80 diseases to diagnose in autoimmune disorders and increase the accuracy of the range of diagnosis.

Market Trends, Drivers, Restraints, and Opportunities

• Vast technical improvement in the field of medical science, partnerships with clinical laboratories and physicians, and advanced laboratory automation are key factors propelling the market.
• Increasing public awareness, high cases of infectious diseases, and rising organizations efforts to cure and diagnose the disease are impacting the market in positive way.
• Prerequisite of high finance in the installment of diagnosis center and lack of access to the advanced healthcare services in developing regions are key challenges that can hamper the market growth.
• Lack of skilled professionals in the under-developed and developing countries as well as time consuming diagnosis and large incidence of false results are projected to impede the market growth.

Scope of the Report

The report on the global autoimmune disease diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Systemic autoimmune diagnostics segment is expected to grow at a robust pace

Based on types, the global autoimmune disease diagnostics market is bifurcated into systemic autoimmune disease diagnostics and localized autoimmune disease diagnostics. The systemic autoimmune disease diagnostics is further segmented into ankylosing spondylitis, rheumatoid arthritis, systemic lupus erythematosus, and others. Meanwhile, the localized autoimmune disease diagnostic is further classified into multiple sclerosis, hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, type 1 diabetes, and others. The systemic autoimmune diagnostics segment is expected to grow at a robust pace during the forecast period. The segment growth is attributed to the prevalence of rheumatoid arthritis along with technological advancements in proteomics technologies and immunofluorescence for rheumatoid arthritis diagnosis. As per a latest report published by the American Autoimmune Related Diseases Association, nearly 50 million Americans were currently suffering from autoimmune disorders and this number was expected to grow in the coming years. However, the localized disease diagnostics segment is projected to register a considerable growth rate in the coming years due to the factors such as the availability of large procedure volumes as well as high patient awareness.

Get Free Sample Report

North America is anticipated to constitute a major market share

In terms of regions, the global autoimmune disease diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major share of the global market during the forecast period owing to the rising implementation of the healthcare policies especially in the US such as Affordable Care Act. The encouraging regulations & initiatives undertaken by the American Autoimmune Related Diseases Association, Inc. (AARDA) made the region a major destination for the market expansion. The aim of this initiative was to reduce the expenses of the disease treatment by diagnosing the disease at an early stage.

The market of Asia Pacific is anticipated to expand at a significant growth rate during the projected period owing to the increasing disposable income and growing patient numbers in developing countries. The local and international players in the region are major contributors to the market growth by adopting the growth strategies to propel the development of the autoimmune disease diagnostics market. For instance, ImmunArray, a molecular device diagnostic company, along with Kindstar Global Co. Ltd, a specialty clinical testing company based in Wuhan, China has established a collaboration to carry out clinical testing for lupus, because of the prevalence of the disease in China in year 2017.

Get Free Sample Report

Segments

• Systemic Autoimmune Disease Diagnostics
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Systemic Lupus Erythematosus
  • Others
• Localized Autoimmune Disease Diagnostics
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Hashimoto's Thyroiditis
  • Idiopathic Thrombocytopenic Purpura
  • Others

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Siemens Healthineers
• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc.
• EUROIMMUN AG
• SQI Diagnostics
• AESKU.Diagnostics GmbH & Co. KG
• Quest Diagnostics
• Crescendo Bioscience, Inc.
• INOVA Diagnostics, Inc.
• bioMerieux SA
• Hemagen Diagnostics, Inc.

Competitive Landscape

The key players in global autoimmune disease diagnostics market include F. Hoffmann-La Roche Ltd; Siemens Healthineers; Beckman Coulter, Inc.; EUROIMMUN AG; SQI Diagnostics; Abbott Laboratories; AESKU.Diagnostics GmbH & Co. KG; Quest Diagnostics; Bio-Rad Laboratories, Inc.; Crescendo Bioscience, Inc.; INOVA Diagnostics, Inc.; bioMerieux SA; and Hemagen Diagnostics, Inc.

One of the major biotech France-based company, bioMerieux SA introduced its VIDAS beta 2 Microglobulin tests, using the ELISA technique for the quantitative measurement in human serum or plasma and urine. Abbott lab. provides specific protein testing for diagnosis of immune-related conditions, such as rheumatoid arthritis. Bio-Rad Laboratories Inc. uses Anti-CCP EIA, an enzyme immunoassay for the identification of autoantibodies for rheumatoid arthritis. Moreover, F. Hoffmann-La Roche Ltd. has conducted Cobas 4000 analyser series, Elecsys Anti-TSHRl, and Cobas 4000 analyser series for autoimmune disease diagnostics.